Daily Mains Practice Question 27-06-2026

What are Fixed Dose Combinations (FDCs)? Discuss their advantages and concerns associated with irrational FDCs in India & the measures taken by the Government to regulate them. (15 marks, 250 words).

For Reference Click Here:   IAS PARLIAMENT                                        THE HINDU

Answer

Introduction:

A Fixed Dose Combination (FDC) is a pharmaceutical product containing two or more active pharmaceutical ingredients (APIs) in a fixed ratio within a single dosage form. While rational FDCs improve therapeutic outcomes, the widespread availability of irrational FDCs has emerged as a major public health concern in India.

Main Body

Advantages of Rational FDCs

• Improved Patient Compliance – Reduces pill burden, improving adherence in chronic diseases.
• Therapeutic Synergy – Complementary drugs enhance efficacy (e.g., TB, HIV, hypertension).
• Reduced Antimicrobial Resistance – Ensures patients receive complete multidrug therapy, reducing resistance in diseases like TB.
• Cost Efficiency – Single formulation lowers manufacturing, packaging and treatment costs.
• Convenience – Simplifies prescribing, dispensing and public health logistics.
• Reduced Medication Errors – Fewer tablets reduce chances of missed or incorrect doses.

Concerns Associated with Irrational FDCs

• Lack of Scientific Evidence – Many combinations lack adequate clinical trials proving safety and efficacy.
  • Example: Amoxicillin + Serratiopeptidase – Antibiotic with anti‑inflammatory enzyme, no proven benefit together.
• Increased Adverse Drug Reactions – Unnecessary drug combinations expose patients to greater risk of toxicity, drug interactions and side effects & also difficulty in identifying the offending drug.
• Antimicrobial Resistance (AMR) – Irrational antibiotic combinations promote indiscriminate antibiotic use which weakens India's National Action Plan on AMR.
• Inappropriate Dosage Ratios – Fixed doses may not suit patients of different ages, weights, or disease severity.
• Unnecessary Financial Burden – Patients pay for medicines containing ingredients they may not require.
• Regulatory Loopholes – States licensed several FDCs without prior approval from the Central Drugs Standard Control Organization, leading to thousands of unapproved products entering the market.
• Ethical Concerns – They undermine individualized therapy, favour marketing over evidence, and breach the principle of “Do No Harm” (non-maleficence).

Government Measures to Regulate Irrational FDCs

• Ban on Irrational FDCs – The Central Government has prohibited hundreds of irrational FDCs in phases under the provisions of the Drugs and Cosmetics Act after expert committee recommendations.
• Strengthening Central Approval – New FDCs require approval under the provisions of the New Drugs and Clinical Trials Rules, 2019 before manufacture.
• Expert Committee Reviews – Committees such as the Kokate Committee reviewed thousands of marketed FDCs for safety, efficacy, and therapeutic justification.
• Strict Licensing – Mandatory clinical evidence and safety data before granting marketing approval for new FDCs.
• Regulatory Coordination – Improved coordination between CDSCO and State Drug Controllers to prevent licensing of unapproved FDCs.
• Digital Drug Regulation – Online drug approval and licensing systems have improved regulatory oversight and transparency.

Conclusion:

Rational FDCs improve treatment adherence, affordability, and therapeutic outcomes, while irrational FDCs endanger patient safety and accelerate antimicrobial resistance. Ensuring evidence-based approvals, strict regulation, robust pharmaco-vigilance, and rational prescribing is essential for their safe and effective use.